Digital Mammography for the Detection and Preoperative Staging of Breast Cancer

Breast Cancer Clinical Trial

Official title:

Dual Energy Contrast Enhanced Digital Mammography for the Detection and Preoperative Staging of Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01086514
• Other study ID #: 10-024
• Status: Completed
• Phase: N/A
• First received: March 11, 2010
• Last updated: September 28, 2015
• Start date: March 2010
• Est. completion date: October 2012

Study information

• Verified date: September 2015
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Breast tumors are normally seen with mammography or ultrasound without the use of a dye but the size and extent of the tumor may be hard to see. Currently, after initial mammography, many patients undergo bilateral breast MR to further stage the local tumor. It is able to not only detect anatomic abnormalities but can also evaluate changes such as the development of new blood vessels, which occurs with the development of cancers. MRI is extremely sensitive and detects unsuspected disease in up to 25% of patients, which affects their treatment. It also detects unsuspected cancer in the other breast in some patients.

However, MRI is expensive, not always available, and some patients are unable to undergo MRI due to the presence of pacemakers, clips, or claustrophobia. Dual Energy Contrast Enhanced Digital Mammography (DE CEDM) is an investigational procedure that uses a non-standard contrast in a regular digital mammography exam that has been changed to give the needed dual energy and image. DE CEDM is not FDA approved. It is our hope that DE CEDM will also be able to detect unknown tumors because it will also detect new blood vessels. It is less expensive than MRI, could be more available to patients, and can be done on patients with pacemakers and clips. Claustrophobia will not be a problem. We plan to see if (DE CEDM) will help us better see the breast tumor and size of the breast tumor. We will also want to see if DE CEDM can detect additional unsuspected disease in the breast with the known tumor and in the other breast without a known tumor.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 82
• Est. completion date: October 2012
• Est. primary completion date: October 2012
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• Women with newly diagnosed unilateral breast cancer proven through core biopsy or FNA who are planned to have (preoperative) MRI within 30 days of DE CEDM to assess extent of disease/multifocality. (All women will have bilateral digital mammography as per standard of care.) The preoperative MRI will be based on the surgeon's recommendation.

• Both breasts are present.

• Women consenting to a bilateral DE CEDM examination.

Exclusion Criteria:

• Women under 21.

• Women who have already had a lumpectomy. (Index lesion has been removed and therefore, not evaluable for the purpose of this study.)

• Women undergoing neoadjuvant chemotherapy, hormone treatment, or radiation therapy.

• Known pregnancy.

• Women who have a contraindication to the intravenous use of iodinated or gadolinium-chelated contrast agent.

• Women with breast implants.

• Women with pacemakers.

• Women with aneurysm clips that don't allow for MRI.

• Women too claustrophobic to undergo MRI.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Procedure:
• Dual Energy Contrast Enhanced Digital Mammography (DE CEDM)
Each patient will have: Bilateral digital mammography, Bilateral Breast MRI, Bilateral Contrast Enhanced Digital Mammography. The latter examination is the only change in patient management. An additional contrast injection is involved. Results of the DE CEDM will be compared with routine digital mammography and breast MRI. The reference standard is pathology. If surgery is to be done; every attempt will be made to perform all imaging exams within 30 days.

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Cancer Center	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center	GE Healthcare

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To estimate additional measures of accuracy of DE CEDM and MRI, such as the predictive values and ROC curves where applicable, for detecting multifocal or multicentric disease in the ipsilateral breast.	Every attempt will be made to perform all imaging exams All examinations will be completed within 30 days of scheduled surgery	within 3 weeks of each other and within 30 days of surgery	No
Secondary	To compare the sensitivity and specificity of DE CEDM with that of breast MRI in the detection of disease in the contralateral breast.	Every attempt will be made to perform all imaging exams All examinations will be completed within 30 days of scheduled surgery	within 3 weeks of each other and within 30 days of surgery	No
Secondary	To estimate the interobserver variability of DE CEDM.	Every attempt will be made to perform all imaging exams All examinations will be completed within 30 days of scheduled surgery	within 3 weeks of each other and within 30 days of surgery	No

External Links

•   Memorial Sloan Kettering Cancer Center